Why One Korean Biotech Picked New Jersey for U.S. Headquarters

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

The Regeneron SVP details the company’s approach to reaching oncology patients across the planet.

The chaotic tariff situation is forcing pharma companies to prepare for multiple outcomes.

While supply chain interruptions are a strong possibility, the tariffs also provide the industry with a chance to improve certain conditions.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses the expansion of its ViraxImmune platform into areas such as transplant monitoring, vaccine efficacy, latent virus reactivation, and CAR T cell therapy.

Nigel McCracken, chief operating officer, Virax Biolabs explains how the ViraxImmune PAIS assay uses T cell responses and cytokine levels to detect immune dysfunction and identify viral triggers of chronic inflammation.